<div id="readability-page-1"><p><span>Fortrea (NASDAQ:FTRE - Get Free Report)</span> was upgraded by equities researchers at Truist Financial from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a report issued on Thursday,Zacks.com reports.</p><p>Other research analysts have also issued research reports about the stock. Mizuho increased their target price on shares of Fortrea from $11.00 to $13.00 and gave the stock a &#34;neutral&#34; rating in a research note on Thursday, December 18th. Zacks Research lowered shares of Fortrea from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Monday, October 20th. Barclays  set a $15.00 target price on shares of Fortrea and gave the company an &#34;equal weight&#34; rating in a report on Monday, December 15th. Evercore ISI  set a $25.00 price target on Fortrea and gave the stock an &#34;outperform&#34; rating in a research note on Tuesday. Finally, Citigroup upgraded Fortrea from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and raised their price target for the stock from $12.00 to $21.00 in a research report on Thursday, December 11th. Two equities research analysts have rated the stock with a Strong Buy rating, three have assigned  a Buy rating, seven have assigned  a Hold rating and one  has issued  a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of &#34;Hold&#34; and an average price target of $16.17.</p><p><b>Get Our Latest Research Report on Fortrea</b></p><h2>Fortrea Trading Down 0.3%</h2><p>Shares of Fortrea stock opened at $17.44 on Thursday. The stock has a 50 day moving average of $14.06 and a 200 day moving average of $10.14. The company has a debt-to-equity ratio of 1.81, a quick ratio of 1.00 and a current ratio of 1.00. The firm has a market capitalization of $1.61 billion, a price-to-earnings ratio of -1.55, a PEG ratio of 0.51 and a beta of 1.59. Fortrea has a fifty-two week low of $3.97 and a fifty-two week high of $19.00. </p><p>Fortrea (NASDAQ:FTRE - Get Free Report) last announced its quarterly earnings results on Wednesday, November 5th. The company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.16 by ($0.04). The business had revenue of $701.30 million during the quarter, compared to analyst estimates of $643.43 million. Fortrea had a negative net margin of 36.77% and a positive return on equity of 5.64%.  As a group, research analysts predict that  Fortrea will post 0.51 earnings per share for the current year. </p><h2>Institutional Investors Weigh In On Fortrea</h2><p>Hedge funds have recently bought and sold shares of the stock. Allworth Financial LP boosted its stake in shares of  Fortrea by 6,802.4% in the 2nd quarter. Allworth Financial LP now owns 5,660 shares of the company's stock valued at $28,000 after buying an additional 5,578 shares during the period.  Nisa Investment Advisors LLC raised its holdings in  Fortrea by 214.3% in the third quarter. Nisa Investment Advisors LLC now owns 3,341 shares of the company's stock valued at $28,000 after acquiring an additional 2,278 shares in the last quarter.  Osaic Holdings Inc. lifted its stake in  Fortrea by 74.3% in the second quarter. Osaic Holdings Inc. now owns 6,844 shares of the company's stock worth $38,000 after acquiring an additional 2,918 shares during the last quarter.  Tower Research Capital LLC TRC lifted its stake in  Fortrea by 137.0% in the second quarter. Tower Research Capital LLC TRC now owns 8,713 shares of the company's stock worth $43,000 after acquiring an additional 5,036 shares during the last quarter.  Finally, Ameritas Investment Partners Inc. acquired a new position in  Fortrea during the 2nd quarter worth approximately $46,000. </p><h2>Fortrea Company Profile</h2> (Get Free Report)<p>Fortrea, Inc is a global contract development and manufacturing organization (CDMO) that provides integrated solutions for pharmaceutical and biotechnology companies. Established as a spin-off from Thermo Fisher Scientific's Pharma Services business in October 2023, Fortrea leverages a legacy of scientific expertise and manufacturing scale to support drug development from early-stage research through commercial production. The company's comprehensive offerings address the complex needs of both small-molecule and biologics programs, making it a single source for clients seeking to accelerate timelines and manage costs.  </p><p>Fortrea's core services encompass analytical and formulation development, process optimization, clinical and commercial manufacturing, and packaging services.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Fortrea</li><li>Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!</li><li>Do not delete, read immediately</li><li>This stock gets a 94 out of 100</li><li>First Time Since 2007: All Warnings Active</li><li>Executive Order 14330: Trump’s Biggest Yet</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RlRSRQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RlRSRQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Fortrea Right Now?</h2><p>Before you consider Fortrea, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fortrea wasn't on the list.</p><p>While Fortrea currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

FTRE

<p>Truist Financial upgraded Fortrea (NASDAQ:FTRE) from a "hold" to a "strong-buy" rating. Other analysts have varied opinions, with Mizuho raising the target price to $13.00 and Barclays setting it at $15.00. Fortrea's stock opened at $17.44, with a market cap of $1.61 billion. The company reported a quarterly EPS of $0.12, missing estimates, but had revenue of $701.30 million. Fortrea, a CDMO, focuses on integrated solutions for pharmaceutical companies, having spun off from Thermo Fisher Scientific in October 2023.</p>

Fortrea (NASDAQ:FTRE) Upgraded to "Strong-Buy" at Truist Financial